The interferon-NUB1-p27Kip1-ERα pathway we propose provides a plausible mechanism for FEC’s differential effects in ER+ versus ER− BC cell lines, warranting further investigation into this pathway’s therapeutic potential. Here, NUB1 is linked to breast cancer.